Epigenetic mechanisms may play an important role in the etiology of endometriosis. The modification of histones by methylation of lysine residues has been shown to regulate gene expression by changing chromatin structure. We have previously shown that endometriotic lesions had aberrant levels of histone acetylation (lower) and methylation (higher) than control tissues. We aimed to determine the levels of trimethylated histone 3 at lysine residue 27 (H3K27me3), a well-known repressive mark, by immunoassay of fresh tissues and immunohistochemistry (IHC) of an endometriosis-focused tissue microarray. Also, we aimed to determine levels of expression of enhancer of zeste homolog 2 (EZH2), the enzyme responsible for trimethylation of H3K27me3, in cell lines. Average levels of H3K27me3 measured by immunoassay were not significantly different in lesions compared to endometrium from patients and controls. However, there was a trend of higher levels of H3K27me3 in secretory versus proliferative endometrium. The results of IHC showed that lesions (ovarian, fallopian, and peritoneal) and secretory endometrium from controls have higher percentage of H3K27me3-positive nuclei than eutopic endometrium from patients. Endometriotic epithelial cells express high levels of EZH2, which is upregulated by progesterone. This study provides evidence in support of a role of H3K27me3 in the pathogenesis of endometriosis and for EZH2 as a potential therapeutic target for this disease, but more studies are necessary to understand the molecular mechanisms at play.
Introduction
Endometriosis is an estrogen-dependent, progesterone-resistant condition that affects 1 of 10 women around the world. 1 Knowledge of the pathophysiology of endometriosis is limited, but genetic, environmental, inflammatory, and, recently, epigenetic factors are known to be involved in this disease. [2] [3] [4] [5] Epigenetic mechanisms exert their biological effects by regulating gene expression via modulation of chromatin structure without affecting the nucleotide sequence. Several epigenetic mechanisms regulate gene expression including promoter methylation at CpG islands and distinct histone modifications including acetylation, methylation, phosphorylation, and sumoylation. [6] [7] [8] Histone methylation is one of the key epigenetic modifications that play a role in several cellular processes via modulation (activation or silencing) of transcriptional activity. This regulation is mediated by changes in the chromatin structure to allow (or block) access to the transcriptional machinery. Specific histones can be methylated at various levels, that is, mono-, di-, or trimethylation, which are correlated with either gene expression or gene repression. Trimethylation of lysine residue 27 at histone 3 (H3K27me3) is a well-known repressive histone modification that silences gene transcription and plays a role in stem cell differentiation and carcinogenesis. [9] [10] [11] Enhancer of Zeste Homolog 2 (EZH2) is the catalytic subunit of the polycomb repressive complex 2, which catalyzes the addition of 3 methyl groups to the lysine residue 27 at histone 3. 10 High levels of H3K27me3 have been observed in different types of cancer including ovarian, prostate, breast, and colon cancers, 12, 13 and its levels can be used as prognosis marker in patients with renal cell carcinoma and pediatric glioblastoma. 14, 15 We have previously shown that endometriotic lesions are characterized by hypoacetylation of H3K9 and H3K16 and hypermethylation of H3K4, H3K9, and H3K27. 16, 17 Based on these findings, we aimed to further study the relevance of H3K27me3 specifically in endometriosis.
The purpose of this study was to determine the levels of H3K27me3 by immunoassay of whole tissues, immunohistochemistry (IHC) of tissue microarray (TMA), and Western blot (WB) of cell line protein extracts. We hypothesized that (1) endometriotic lesions and endometrium of patients are characterized by higher levels of H3K27me3 than control tissues (eutopic endometrium) and (2) the expression of EZH2, the histone methyltransferase (HMT) responsible for catalyzing H3K27 trimethylation, is regulated by ovarian steroid hormones in endometriotic epithelial cell lines. Our data suggest that H3K27me3 may play a role in the different mechanisms at play in endometriosis. Since histone methylases and demethylases have been proposed as potential new therapies for endometriosis, 18 these results are of great translational value.
Materials and Methods

Tissue Collection
Fresh tissues (endometriotic lesions [n ¼ 14], eutopic endometrium from patients [n ¼ 17], and eutopic endometrium from controls [n ¼ 15]) were obtained from premenopausal women aged 16 to 49 years with and without endometriosis during surgery and immediately frozen at À80 C after collection. Cases are defined as women with surgically diagnosed endometriosis and controls were women undergoing surgery for benign gynecologic conditions (ie, fibroids) who were found not to have endometriosis during surgery. The tissues were analyzed by histopathology to confirm endometriosis, defined as the presence of endometrial glands and stroma, and if is endometriosis, to date the menstrual cycle phase according to Noyes. 19 Demographic profiles of patients used for detection of H3K27me3 status by enzyme-linked immunosorbent assay in the study are presented in Table 1 .
Cell Culture and Ovarian Steroid Hormone Treatments
Human epithelial cells EEC/MCF-7, a nonendometriotic epithelial cell line, and human endometriotic epithelial cells (12Z; gifts from Dr A. Fazleabas and Dr A. Starzinski, respectively) were used for the experiments. 20 The EEC/MCF-7 cells were cultured in Dulbecco Modified Eagle Medium (DMEM)/F-12 Nutrient Mixture supplemented with 10% fetal bovine serum (FBS), 1% ampicillin/streptomycin antibiotic, 160 ng/mL of bovine insulin at 37 C, and 5% CO 2 . The 12-Z cells were grown in DMEM/F12 with phenol red complete media supplemented with 10% FBS, 1% ampicillin/streptomycin antibiotic, and 1% of sodium pyruvate. The EEC/ MCF-7 and 12Z cells were grown to confluence in normal complete media and split into 25 cm 2 tissue culture flasks at a cell density of 1.0 Â 10 6 cells. Once cells reached 85% confluence, they were cultured in deprived media for 24 hours. On day 1, cells were incubated with physiological levels (10 À8 mol/L of estrogen [E 2 ] and 10 À7 mol/L of progesterone [P 4 ]) of steroid hormones, alone or in combination, diluted in deprived media. Control cells received only deprived media.
Protein Extraction and WB Analysis
Briefly, 90% confluent cells growing in log phase were washed with 10 mmol/L cold PBS followed by a centrifugation of 1500 rpm for 5 minutes at 4 C. Then, cell pellet was washed again with for 10 mmol/L cold PBS followed by a centrifugation of 1500 rpm for 5 minutes at 4 C. Cell pellets were lysed by resuspending the pellet in lysis buffer (50 nmol/L Tris-HCl [pH 7.5], 150 mmol/L NaCl, 1% NP-40, 1 mmol/L Na 3 VO 4 , and 1 mmol/L NaF) supplemented with protease and phosphatase inhibitors (Roche, Indianapolis, Indiana). For WB analysis, equal amounts of proteins (10 mg) were separated on a 10% sodium dodecyl sulfatepolyacrylamide gel. Membranes were blocked for 2 hours in blocking buffer (20 mol/L Tris-HCl, 150 mol/L NaCl, 5% nonfat dry milk, and 0.1% Tween 20) at room temperature. Blots were incubated overnight at 4 C with EZH2 1:1000 (Epigentek, Brooklyn, New York). After overnight incubation, membranes were washed and incubated with horseradish peroxidaseconjugated secondary antibody (Sigma, St Louis, Missouri) at room temperature for 1 hour. Proteins were visualized with an automated image documentation system (ChemiDoc, Bio-Rad, Hercules, California) and band density analyzed using Quantity One software (Bio-Rad). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein was used for normalization purposes.
Lysine 27 Trimethylation at Histone 3 Immunoassay
Assessment of H3K27me was conducted using the EpiQuick Immunoassay kit (Epigentek) specific for histone 3 lysine 27 trimethylated following the manufacturer's protocol. In brief, protein samples from whole tissue (200 ng/mL) were added to the wells and incubated according to the protocol. Next, colorimetric analysis was performed using a microplate reader. The amount of methylated protein was obtained by subtracting the methylated protein amount by the total protein amount by the protein input amount and divided by the slope. Two technical replicates were performed for validation purposes.
Immunohistochemistry of H3K27me3 in Human Endometrial and Endometriotic Samples on a TMA
A total of 164 formalin-fixed, paraffin-embedded endometrium and endometriosis tissues were used to construct a TMA at Moffitt Cancer Center. 16 All the biopsies were evaluated by a pathologist to confirm the diagnosis of endometriosis. The total number of cores in the TMA were 34 peritoneal endometriosis, 29 ovarian endometriosis, 16 fallopian endometriosis, 7 gastrointestinal (GI) endometriosis, 4 skin endometriosis, 38 secretory phase endometrium, 14 control proliferative phase endometrium, and 22 eutopic endometrium of women with endometriosis. Control endometria were obtained from patients with other gynecological conditions different to endometriosis. The average age of the patients and controls was 35 and 42 years, respectively.
Immunostaining of H3K27me3 was conducted following standard protocols. Briefly, after paraffin removal and dehydration, antigen unmasking was performed. Peroxidase blocking was conducted and the TMA was incubated with the primary antibody H3K27me3 (1:100) (Epigentek) at 4 C overnight. To amplify and detect the primary antibody signal, we used the labeled streptavidin binding method following the manufacturer's protocol (DAKO, Carpinteria, California). For staining and counterstaining of the TMA, DAB and hematoxylin (Fischer Scientific, Waltham, Massachusetts) were used, respectively. The slide was mounted and visualized at 20Â, 40Â, and 100Â magnification on an inverted microscope with an Olympus 35 mm camera (Nikon, Japan). The Image Scope Software was used to select the areas for analysis (eg, glands and stroma). The Aperio Immunostaining Analysis System available through the Imaging Core from Moffitt Cancer Center was used to evaluate the intensity of H3K27me3 in the endometrial and endometriotic tissues on the TMA. Data were analyzed as percentage of positive nuclei and HistoScore in glands and stroma. HistoScore is obtained from the formula (3 Â percentage of strongly staining nuclei) þ (2 Â percentage of moderately staining nuclei) þ (percentage of weakly staining nuclei), giving a range of 0 to 300. 
Statistical Analyses
Nonparametric statistics analysis of variance and Dunn Multiple Comparison posttest were performed using GraphPad Prism 4.0 (GraphPad Software Inc, La Jolla, California) to determine statistical significance between the study groups. Statistical significance was set at P < .05.
Results
Levels of H3K27me3 in Endometriotic and Endometrial Tissues Measured by Immunoassay
As shown in Figure 1A , the average total levels of H3K27me3 were not significantly different (P ¼ .6273) in endometriotic lesions compared to eutopic endometrium from patients and from controls. No significant differences by menstrual cycle phase were found either (P ¼ .4895) between groups, but levels tended to be higher in secretory endometria ( Figure 1B ).
Percentage of H3K27me3 Positive Nuclei in Endometriotic and Endometrial Tissues on a TMA
The percentage of H3K27me3 (H3K27me3%) positive nuclei was analyzed in different lesion types (ovarian, peritoneal, fallopian, skin, and gastrointestinal [GI (cecum and appendix)]), endometrium from cases, and endometrium from controls on a TMA. Nuclear immunostaining specific for H3K27me3 was detected in both glands and stroma in lesions and endometria. Figure 2 shows representative pictures of the stained TMA showing different levels of staining intensity. No significant differences in percentage of positive nuclei were observed among lesion type in either glands or stroma. Significantly higher levels of H3K27me3% positive nuclei were observed in stroma of lesions and secretory endometrium from controls compared to proliferative endometrium from cases ( Figure  3) . Similar results were observed for glands; however, levels of H3K27me3 in lesions were not significantly different compared to proliferative endometrium from cases. Based on the HistoScore, the average intensity of the H3K27me3-specific immunostaining of glands was significantly higher in secretory endometrium compared to proliferative endometrium from both cases and controls. However, no significant differences were found between lesions and control tissues (Figure 4 ). In stroma, the average intensity of H3K27me3 was not significantly different between lesions and control tissues. Also, we did not observe significant differences in the proportion of tissues showing strong nuclear staining of H3K27me3 in >50% of nuclei between groups (data not shown).
Progesterone Increases Expression of EZH2 in Endometriotic Epithelial Cells (12Z)
The EZH2 expression profile was analyzed in an endometriotic cell line (12Z) and a nonendometriotic epithelial cell line H3K27me3 levels were determined using the EpiQuick Tri-methylation Assay Kits (Epigentek, Brooklyn, New York) following the manufacturer's protocols. The amount of methylated protein in nanograms per milligrams of total protein was obtained dividing the methylated protein amount and the total protein input amount divided by the slope. Average total trimethylation levels at H3K27me3 were not significantly different (P ¼ .6273) in endometriotic lesions as compared to eutopic endometrium from patients and from controls. Endometriotic lesions (n ¼ 14), endometrium from women with endometriosis (n ¼ 17), and endometrium from controls (n ¼ 15).
(EEC/MCF7). Western blot analysis showed that under basal conditions (no treatment), the endometriotic epithelial cells but not the nonendometriotic epithelial cells expressed EZH2. Also, we observed that EZH2 expression was upregulated by progesterone treatment (Figure 5 ) only in 12Z cells.
Discussion
Epigenetic mechanisms are emerging as important players in the pathophysiology of endometriosis; however, data are limited and the role of histone methylation in endometriosis is not well understood. 2, 21, 22 It is well known that promoter regions of endometriosis candidate genes such as HOXA10, CDH1, and PGR are hypermethylated contributing to defects in uterine receptivity, invasiveness of endometrial cells, and progesterone resistance, respectively. 23 DNA methylation is known to work together with histone modifications to regulate gene expression. H3K27me3 is a repressive histone mark shown to be closely related to CpG-islands in promoter regions, suggesting a link between histone methylation and DNA methylation. 24 H3K27me3 plays roles during embryogenesis, cell decidualization, tissue regeneration, and pathological states such as HistoScore for all types of lesions was shown in (A) and (B). Intensities staining for lesions taking together as a group were showed for stroma (A) and glands (B). One-way analysis of variance (ANOVA) was carried out among endometriotic lesion locations and the proliferative endometrium from patients and proliferative and secretory endometrium from controls. Analysis was conducted separately for stroma and glands. Figure 5 . Expression of enhancer of zeste homolog 2 (EZH2) on epithelial endometriotic cells (12Z) and nonendometriotic epithelial cells (EEC/MCF7) with ovarian steroid hormones. EZH2 HMT for H3K27me3 was detected at % 75 to 100 kDa. Total protein of hormonetreated cells (10 mg/mL) was extracted and subjected to Western blot using EZH2 polyclonal antibody. Cells were treated with estrogen (E2), progesterone (P4), and E2/P4 at 24 hours. The concentration of E2 used was 1 Â 10 À8 . P4 concentration used was 1 Â 10 À7 . Internal control was GAPDH % 37 kDa. Relative densitometry is shown for 3 independent experiments for the 24-hour time point, optical density (OD) units were normalized against GAPDH and presented relative to basal. cancer. [25] [26] [27] [28] [29] [30] However, the levels of and potential involvement of histone marks in gene expression changes leading to endometriosis are still unknown. This study shows for the first time that endometriotic lesions are characterized by high levels of H3K27me3, which may have pathophysiological and also therapeutic implications.
Although immunoassay results did not show differences in the levels of H3K27me3 in lesions compared to control tissues (endometria from patients and controls), analysis was done on samples representing whole tissues, with varying stromal versus gland ratios. Also, we analyzed a mixture of different lesion types of tissues and clinical presentations. No significant differences were found based on the menstrual cycle phase, but H3K27me3 levels in the secretory phase tended to be higher in eutopic endometrium from patients and controls. This suggests that levels of this histone mark are marginally regulated by progesterone. Previous studies in our laboratory showed that methylation levels of H3K27 were significantly higher in endometriotic lesions and endometrium from patients compared to endometrium of controls, using an immunoassay that does not distinguish among mono-, di-, and trimethylation. 17 The molecular roles of H3K27me1, H3K27me2, and H3K27me3 are known to be different; therefore, it is important to elucidate their respective levels in endometriosis tissues and also to take into account cellular compartment (stroma vs glands). In order to do so and to validate the results obtained with the immunoassay analysis, we analyzed the levels of H3K27me3 in human endometriotic and endometrial tissues on a TMA by IHC.
Based on the percentage of positive nuclei, the levels of H3K27me3 in the glands and stroma of endometriotic lesions (ovarian, peritoneal, and fallopian) were higher than in eutopic endometrium of patients, and this difference reached statistical significance in stroma. In glands, H3K27me3 levels were significantly higher when fallopian tube lesions were excluded from the analysis, which indicates that there are differences based on tissue localization/lesion type. The high interindividual variability observed in the lesions is not expected to be different due to menstrual phase based on the immunoassay results ( Figure 1 ); rather this variability may be related to clinical differences (eg, severity, years with disease, symptoms). The differences observed in H3K27me3 levels in endometrium from patients measured by immunoassay versus IHC can be explained by the fact that the immunoassay included samples in both proliferative and secretory phases, while endometrium from patients in the TMA was only in the proliferative phase. Not only was the percentage of positive nuclei higher in lesions and secretory endometrium from controls compared to proliferative endometrium but also the staining intensity was stronger in these tissues based on HistoScore analysis. These data suggest a potential effect of progesterone in the setting of H3K27me3, perhaps via increases in the expression of EZH2, which we studied next.
Western blot analysis demonstrated that expression of EZH2 by the endometriotic epithelial cell line 12Z was higher at the basal level compared to a control cell line. Protein levels of EZH2 increased in the presence of progesterone only in the endometriotic cells, and none of the ovarian steroid hormone treatments induced expression of EZH2 in the control cell line. These results suggest that EZH2 may be a potential specific target for therapy in endometriosis. Our study is the first to show that the expression of EZH2 is regulated by progesterone, which is in accord with the higher levels of H3K27me3 observed in secretory endometrium. Additional studies are warranted to elucidate a potential role of progesterone in the expression of EZH2 and thus setting of the H3K27me3 histone mark in the context of endometriosis.
In primary human epithelial ovarian cancer cells, EZH2 is overexpressed and its expression correlates with higher expression levels of Ki67, which is a marker of increased proliferation. 13 Different hormone-dependent diseases, including breast, prostate, and endometrial cancers, are characterized by aberrant expression of EZH2 and H3K27me3. 31 H3K27me3 modulates gene expression in different cancer types and processes such as inflammation, migration and metastasis, proliferation, and angiogenesis, [32] [33] [34] [35] [36] [37] and these processes were blocked by EZH2 inhibition resulting in reduction of H3K27me3. 38, 39 Chromatin (Ch) Immunoprecipitation (IP) -bisulfite sequencing (ChIPbisulfite-seq) studies demonstrated that CpG islands in promoter regions of cancer cells are characterized by high H3K27me3 levels compared to normal cells 40 and that occupancy of EZH2/ H3K27me3 in gene loci is associated with downregulation of genes that regulate stem cells, apoptosis, and cell growth, respectively. 41, 42 Trimethylation of H3K27 has been shown to be involved in other normal physiology as well as pathological processes. This histone mark blocks the transition from a proliferative to a decidual phenotype in the endometrium, 28 suppresses the expression of developmental genes such as the HOX genes, 43 and causes COX-2 gene repression and decreases the levels of PGE2. 44 All these cellular processes have been shown to be involved in the pathophysiology of endometriosis, which supports future investigations on the role of the H3K27me3 histone mark in this disease.
The strengths of this study are that we used an endometriosis focused-TMA to assess the nuclear immunostaining of H3K27me3 in different tissue types (eg, lesions, eutopic endometrium from cases, and controls) and cellular compartments (stroma and gland), but more studies are necessary to uncover potential differences based on disease severity or clinical presentation, including assessment of this histone mark in deeply infiltrating lesions. Despite limitations of this study, including the small sample size of the immunoassay, as well as heterogeneity in the cellular composition of the lesions and menstrual cycle phase, these data have important clinical implications. H3K27me3 may be a potential biomarker for endometriosis (its levels were significantly higher in endometria from controls versus endometria from patients, in both glands and stroma); also, EZH2, the enzyme that catalyzes trimethylation of H3K27, may be a novel therapeutic target in endometriosis based on our results showing increased expression of this enzyme in endometriotic cells. Finally, this epigenetic mark may be an important mechanism for regulation of gene expression in this disease. Ongoing studies in our laboratory include assessment of levels of EZH2 and other HMTs in tissues, and ChIP analysis to profile the H3K27 methylation status near or within the promoter region of candidate genes for endometriosis.
